Kyverna Therapeutics, Inc.
mivocabtagene autoleucel
stiff person syndrome
Date
TBD
Phase 2 readout · Date TBD estimated
What's at stake
Phase 2 trial results for mivocabtagene autoleucel in stiff person syndrome are due Date TBD. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 14h ago
“In October 2025, Kyverna reported positive interim data from the Phase 2 portion of its KYSA-6 clinical trial.”